Propanc Biopharma, Inc.
PPCBNASDAQHealthcareBiotechnology
Regular session
$1.11
+$0.03 · +2.78%
PPCB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
17
Strong Down
Sentiment
53
Mixed
Risk resilience
11
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePropanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- AU
- CEO
- James Nathanielsz
- Listed since
- Nov 12, 2012
- Employees
- 2
Market position
Day range
Current $1.11
52-week range
Current $1.11
- Open
- $1.1336
- Previous close
- $1.08
- Volume
- 17.58K
- 0× average
- Average volume
- 3.9M
- Average daily volume
- Market cap
- 2.53M USD
- Beta
- 3.27
- Market reference 1
- 50-day average
- $1.45
- -23.45% below average
- 200-day average
- $6.7471
- -83.55% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 18.18M USD
- EV / EBITDA
- -0.31×
- Earnings yield
- -357.81%
- Free cash flow yield
- -2.46%
Profitability & efficiency
- Return on equity
- -423.72%
- Return on assets
- -300.14%
- Return on invested capital
- -366.39%
Financial health
- Current ratio
- 1.5×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 21.66K USD | 17.76K USD | — | — |
| Gross profit | — | −21.66K USD | −17.76K USD | −5.67K USD | — |
| Research and development | 223.72K USD | 248.1K USD | 247.92K USD | 256.05K USD | 230.96K USD |
| Selling, general, and administrative | 57.05M USD | 1.29M USD | 1.53M USD | 1.73M USD | 1.58M USD |
| Operating expenses | 57.28M USD | 1.51M USD | 1.76M USD | 1.99M USD | 1.81M USD |
| Interest income | 9 USD | 60 USD | 36 USD | 5.61K USD | — |
| Interest expense | 563.76K USD | 665.84K USD | 532.82K USD | 568.8K USD | 449.46K USD |
| Depreciation and amortization | 20.19K USD | 21.66K USD | 22.93K USD | 1.99K USD | 1.99K USD |
| Operating income | −57.28M USD | −1.54M USD | −1.78M USD | −1.99M USD | −1.81M USD |
| Net income | −58.92M USD | −1.82M USD | −2.66M USD | −2.66M USD | −2.03M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -7
EPS: actual versus estimate
Recent quarterly results
PPCB peers
Continue in GoAI
Research PPCBresearch.disclaimer